24/7 Customer Support

Idiopathic Pulmonary Fibrosis Market – Industry Dynamics, Market Size, and Opportunity Forecast to 2030

Global Idiopathic Pulmonary Fibrosis Market By Therapy (Esbriet (Pirfenidone), Ofev (Nintedanib), Tipelukast, Pamrevlumab, KD025, PRM 151, GKT831, Others); By Region (United States, EU5 (Germany, Spain, Italy, France, United Kingdom), and Japan)- Insights, Epidemiology and Forecast– 2030

  • Published Date: Jul-2021  |   Format: pdfpowerpointexcel  |  Report ID: AA0721084  | Delivery: 2 to 4 Hours
Idiopathic Pulmonary Fibrosis Market

View Full Infographic


Idiopathic pulmonary fibrosis (IPF) is a kind of lung disease that results in scarring (fibrosis) of the lungs for an unknown reason. Over the time, fibrosis gets worse, and it becomes difficult to breathe properly. 

The cost associated with IPF treatment to the healthcare system lies around USD 2 billion for the aged population, whereas the annual direct medical costs of the same treatment for the IPF patient within the USA is around two-fold higher. The high cost of the drugs associated with idiopathic pulmonary fibrosis retards the patients from using or continue taking the drugs.

This report provides analysis of the global Idiopathic Pulmonary Fibrosis market for the period 2017 to 2027, wherein 2017-2019 represent historic data, 2020 is considered as base year. 2021 has been estimated for recent concluded quarter, while 2021-2030 are forecast values, reflecting impact of different factors on the growth trend.

Boehringer Ingelheim GmbH, Cipla Inc, Biogen Inc, Fibrogen Inc., Bristol-Myers Squibb Company and Merck & Co., Inc are the major players in the market

Idiopathic Pulmonary Fibrosis Market is growing at a CAGR of 9.4 % from 2020 to 2030.

Growing geriatric population and increase in number of smokers are likely to drive the market. 

Pulmonary Fibrosis Foundation (PFF), National Organization for Rare Disorder, Global Fibrosis Foundation, and Lung Transplant Foundation are some of the organizations that have contributed towards IPF

United States holds the highest share of market with CAGR of 9.9%

There were 1,11,688 cases of IPF in the year 2020 and is expected to rise 1,97,825 by 2030 and is most likely to be found in people of 81 years and above.

The need can be divided into two types environmental and clinical. Few needs that need to be met are early diagnosis, improved drug safety and efficacy, improvement in patient quality of life and treatment for patients with severe disease 

Esbriet is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF).

The key strategies adopted by market players include mergers and acquisitions, partnerships, regional expansion, and new product development.